Feng Si-Shen is a leading pioneer in nanomedicine. He graduated from Beijing (Peking) University in 1968 (six- year regimen). He obtained his master’s degree from Tsinghua University, Beijing, in 1981 and his PhD in bioengineering from Columbia University, New York, in 1988, under the advisorship of Prof Richard Skalak and Prof Shu Chien. He completed his postdoctoral training in the Columbia University School of Physicians and Surgeons and then worked as a research scientist in Northwestern University Department of Biochemistry, Cell and Molecular Biology. He joined National University of Singapore (NUS) in 1996, where he now holds a joint appointment with the Departments of Chemical and Biomolecular Engineering and Bioengineering. His research interests include cellular and molecular biomechanics, biomembranes, biomaterials, cancer nanobiotechnology, and nanomedicine. Prof Feng also established the Chemotherapeutic Engineering Laboratory in NUS. He is associate editor of the journal Biomaterials (2011 JIF = 7.404), one of the top five journal among the more 2000 journals published by Elsevier. He is also in the editorial boards of all three Elsevier journals in nanomedicine: Nanomedicine-UK (2011 JIF = 5.055, associate editor), Nanomedicine-NBM (2011 JIF = 6.692), and International Journal of Nanomedicine (2011 JIF = 4.424), as well as of other journals, such as Journal of Biomedical Nanotechnology, Liver Cancer Review Letters, Recent Patents on Drug Delivery & Formulation, BSP: The Open Breast Cancer Journal, and Chinese Journal of Biomedical Engineering. He is visiting professor and int’l advisor in some of the top universities in China, including Tsinghua University Shenzhen Graduate School, Nankai University, Shandong University, Huazhong University of Science and Technology, Tongji Medical College, Chinese Academy of Medical Sciences, and Peking Union Medical College’s Institute of Biomedical Engineering. Prof Feng is winner of 2012 Leading Talent Award in Nano. He is also president of Suzhou NanoStar Biopharm Inc. Ltd.

• Introduction. Chemotherapeutic Engineering: Concepts. Chemotherapeutic Engineering: Feasibility. Chemotherapeutic Engineering: Further Proof-of Concept Experimental Results. Chemotherapeutic Engineering: Drug Targeting. Chemotherapeutic Engineering: Multifunctional Nanoparticles. Chemotherapeutic Engineering: Prodrugs. Chemotherapeutic Engineering: Oral Chemotherapy. Chemotherapeutic Engineering: Drug Delivery across the Blood-Brain Barrier. Chemotherapeutic Engineering: Multimodal Imaging. Molecular biomaterials for Nanomedicine.